» Articles » PMID: 28851894

Activated Mesenchymal Stem Cells Interact with Antibiotics and Host Innate Immune Responses to Control Chronic Bacterial Infections

Overview
Journal Sci Rep
Specialty Science
Date 2017 Aug 31
PMID 28851894
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic bacterial infections associated with biofilm formation are often difficult to resolve without extended courses of antibiotic therapy. Mesenchymal stem cells (MSC) exert antibacterial activity in vitro and in acute bacterial infection models, but their activity in chronic infection with biofilm models has not been previously investigated. Therefore, we studied the effects of MSC administration in mouse and dog models of chronic infections associated with biofilms. Mice with chronic Staphylococcus aureus implant infections were treated by i.v. administration of activated or non-activated MSC, with or without antibiotic therapy. The most effective treatment protocol was identified as activated MSC co-administered with antibiotic therapy. Activated MSC were found to accumulate in the wound margins several days after i.v. administration. Macrophages in infected tissues assumed an M2 phenotype, compared to untreated infections which contained predominately M1 macrophages. Bacterial killing by MSC was found to be mediated in part by secretion of cathelicidin and was significantly increased by antibiotics. Studies in pet dogs with spontaneous chronic multi drug-resistant wound infections demonstrated clearance of bacteria and wound healing following repeated i.v. administration of activated allogeneic canine MSC. Thus, systemic therapy with activated MSC may be an effective new, non-antimicrobial approach to treatment of chronic, drug-resistant infections.

Citing Articles

Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.

Hoseinzadeh A, Esmaeili S, Sahebi R, Melak A, Mahmoudi M, Hasannia M Stem Cell Res Ther. 2025; 16(1):33.

PMID: 39901306 PMC: 11792531. DOI: 10.1186/s13287-025-04158-z.


Beyond antibiotics: mesenchymal stem cells and bacteriophages-new approaches to combat bacterial resistance in wound infections.

Teymouri S, Yousefi M, Heidari S, Farokhi S, Afkhami H, Kashfi M Mol Biol Rep. 2024; 52(1):64.

PMID: 39699690 DOI: 10.1007/s11033-024-10163-x.


Equine bone marrow-derived mesenchymal stromal cells reduce established S. aureus and E. coli biofilm matrix in vitro.

Khatibzadeh S, Dahlgren L, Caswell C, Ducker W, Werre S, Bogers S PLoS One. 2024; 19(10):e0312917.

PMID: 39480794 PMC: 11527187. DOI: 10.1371/journal.pone.0312917.


Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.

Bacsur P, Shaham D, Serclova Z, Resal T, Farkas B, Sarlos P Aliment Pharmacol Ther. 2024; 61(2):335-345.

PMID: 39468719 PMC: 11671715. DOI: 10.1111/apt.18359.


Effects of Staphylococcus aureus on stem cells and potential targeted treatment of inflammatory disorders.

Liu Z, Liu G, Lin Z, Chen Y, Chen P, Hu Y Stem Cell Res Ther. 2024; 15(1):187.

PMID: 38937829 PMC: 11210046. DOI: 10.1186/s13287-024-03781-6.


References
1.
Serbina N, Hohl T, Cherny M, Pamer E . Selective expansion of the monocytic lineage directed by bacterial infection. J Immunol. 2009; 183(3):1900-10. PMC: 2753883. DOI: 10.4049/jimmunol.0900612. View

2.
Kim W, Park B, Sung J . The wound-healing and antioxidant effects of adipose-derived stem cells. Expert Opin Biol Ther. 2009; 9(7):879-87. DOI: 10.1517/14712590903039684. View

3.
Gupta K, Singh S, van Hoek M . Short, Synthetic Cationic Peptides Have Antibacterial Activity against Mycobacterium smegmatis by Forming Pores in Membrane and Synergizing with Antibiotics. Antibiotics (Basel). 2016; 4(3):358-78. PMC: 4790291. DOI: 10.3390/antibiotics4030358. View

4.
Hutchins N, Unsinger J, Hotchkiss R, Ayala A . The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med. 2014; 20(4):224-33. PMC: 3976785. DOI: 10.1016/j.molmed.2014.01.002. View

5.
Waterman R, Tomchuck S, Henkle S, Betancourt A . A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010; 5(4):e10088. PMC: 2859930. DOI: 10.1371/journal.pone.0010088. View